New combo aims to keep prostate cancer in check with lower chemo dose
NCT ID NCT07503379
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while reducing the harsh side effects of full-dose chemo. About 109 men will take part in this single-arm trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MHSPC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Cancer Hospital of Guangzhou Medical University
Guangzhou, China
-
Meizhou People's Hospital
Meizhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.